| Allergic Conjunctivitis
Bepreve vs Dextenza
Side-by-side clinical, coverage, and cost comparison for allergic conjunctivitis.Deep comparison between: Bepreve vs Dextenza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDextenza has a higher rate of injection site reactions vs Bepreve based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dextenza but not Bepreve, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bepreve
Dextenza
At A Glance
Ophthalmic
Twice daily
H1-receptor antagonist
Intracanalicular insert
Single insert (up to 30 days)
Corticosteroid
Indications
- Allergic Conjunctivitis
- Inflammatory abnormality of the eye
- Allergic Conjunctivitis
Dosing
Allergic Conjunctivitis Instill one drop into the affected eye(s) twice a day; remove contact lenses prior to instillation.
Inflammatory abnormality of the eye, Allergic Conjunctivitis Single intracanalicular insert releasing 0.4 mg dexamethasone for up to 30 days, placed into the lower lacrimal canaliculus; resorbable, does not require removal.
Contraindications
- History of hypersensitivity reactions to bepotastine or any of the other ingredients
- Active corneal, conjunctival, or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, or varicella
- Mycobacterial infections of the eye
- Fungal diseases of the eye
- Dacryocystitis
Adverse Reactions
Most common (>=25%) Mild taste following instillation
Common (2-5%) Eye irritation, headache, nasopharyngitis
Postmarketing Hypersensitivity reactions including itching, body rash, and swelling of lips, tongue and/or throat
Most common (>=1%) anterior chamber inflammation (including iritis and iridocyclitis), intraocular pressure increased, visual acuity reduced, cystoid macular edema, corneal edema, eye pain, conjunctival hyperemia, lacrimation increased, eye discharge, headache
Serious intraocular pressure increase, bacterial infection, viral infection, fungal infection, delayed healing
Pharmacology
Bepotastine is a topically active, direct H1-receptor antagonist and inhibitor of histamine release from mast cells, administered as an ophthalmic solution for allergic conjunctivitis.
Corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bepreve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Dextenza
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Bepreve
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Dextenza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bepreve
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Dextenza
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bepreve.
No savings programs available for Dextenza.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BepreveView full Bepreve profile
DextenzaView full Dextenza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.